Bicyclol: A novel drug for treating chronic viral hepatitis B and C

Medicinal Chemistry

Volumn 5, Issue 1, 2009, Pages 29-43

  Liu, Geng Tao ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Adefovir; Apoptosis; Bicyclol; Chronic viral hepatitis; Combination therapy; Lamivudine; New drug; Pegylated interferon

Indexed keywords

4,4' DIMETHOXY 5,6,5',6' DIMETHYLENE DIOXYBIPHENYL 2,2' DICARBOXYLATE DIMETHYL ESTER; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BICYCLOL; FOSCARNET; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; LAMIVUDINE; PLACEBO; PLANT MEDICINAL PRODUCT; RIBAVILIN; SCHIZANDRIN C; UNCLASSIFIED DRUG; BIPHENYL DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIVIRAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEMICAL MODIFICATION; CHINA; CHINESE MEDICINE; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DIZZINESS; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FECES LEVEL; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG URINE LEVEL; FOOD AND DRUG ADMINISTRATION; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; LIVER FIBROSIS; LIVER INJURY; LIVER PROTECTION; MEMBRANE STABILIZATION; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; SCHISANDRACEAE; SEROCONVERSION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS; VIRUS INHIBITION; VIRUS MUTANT; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; REVIEW;

ANIMALS; ANTIVIRAL AGENTS; BIPHENYL COMPOUNDS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; MOLECULAR STRUCTURE;

EID: 62649142429     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340609787049316     Document Type: Article

References (53)

1. Yeh, S.H.; Chen, D.S.; Chen, P.J. A prospect for pharmacogenomics in the interferon therapy of chronic viral hepatitis. J. Antimicrob. Chemother., 2003, 52, 149-151.
2. Lia, Y.F. Therapy of chronic hepatitis B: current challenges and opportunities. J. Viral Hepatol., 2002, 99(6), 393-399.
3. Borgia, G.; Gentile, I. Treating chronic hepatitis B: today and tomorrow. Curr. Med. Chem., 2006, 13, 2839-55.
4. Wong, S.N.; Lok, A.S. Update on viral hepatitis: 2005. Curr. Opin. Gastroenterol., 2006, 22(3), 241-247.
5. Liu, G.T. Therapeutic effects of biphenyl dimethyl dicarboxylate (DDB) on chronic viral hepatitis B. Proc. CAMS. PUMC., 1987, 2(4), 228-232.
6. Liu, G.T. The anti-virus and hepatoprotective effect of bicyclol and its mechanism of action. Chin. J. New Drugs, 2001, 10, 325-327.
7. b Hu, Wei.; Li,Y.; Zhang, C.Z. Enantioseparation of racemic antihepatitis new drug. bicyclol with crystallization. Chin. Chem. Lett., 2005, 16(11), 1471-1473.
8. 4-induced liver injury in mice. Liver Int., 2005, 25, 872-879.
9. Wang, H.P.; Li, Yan. Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharides and D-galactosamine in mice. Eur. J. Pharmacol., 2006, 534, 194-201.
10. Zhao, D.M.; Liu, G.T. Protective effect of bicyclol on acetaminophen induced liver mitochondria injury in mice. Chin. J. New Drugs, 2002, 11, 536-540.
11. Li, Y.; Dai, G.W.; Li. Y.; Liu, G.T. Effect of bicyclol on acetaminophen-induced hepatotoxicity: Energy metabolism and mitochondrial injury in acetaminophen intoxicated mice. Acta Pharmacol. Sin., 2001, 36, 723-726.
12. Zhao, D.M.; Liu, G.T. Protective effect of bicyclol on concanavalinA-induced liver nuclear DNA injury in mice. Natl. Med. J. China, 2001, 81(14), 844-848.
13. Kaplowitz, N. Mechanism of liver injury. J. Hepatol., 2000, 32, 39-43.
14. Rust, C.; Gores, G.J. Physiology in Medicine. Apoptosis and liver disease. Am. J. Med., 2000, 108, 567-571.
15. Li, M.; Liu, G.T. Inhibition of Fas/FasL mRNA expression and TNF-a release in concanavalin A-induced liver injury in mice by bicyclol. World J. Gastroenterol., 2004, 10(12), 1775-1779.
16. Li, M. Liu, G.T. Inhibitory effect of bicyclol on iNOS expression and NF-KB activation degradation in macrophages induced by lipopolysaccharides. Chin. Pharmacol. Bull., 2006, 22(12), 1438-1443.
17. Hartl, F.U. Molecular chaperones in cellular protein folding. Nature, 1996, 381, 571-579.
18. Fink, A.L. Chaperone-mediated protein folding. Physiol. Rev., 1999, 79, 425-449.
19. Jaattela, M. Heat shock proteins as cellular lifeguards. Ann. Med., 1999, 31, 261-271.
20. Kultz, D. Molecular and evolutionary basis of the cellular stress response. Ann. Rev. Physiol., 2005, 67, 225-257.
21. Bao, X.Q.; Liu, G.T. Bicyclol: A novel anti-hepatitis drug with hepatic heat shock protein27/70 inducing activity and cytoprotective effects in mice. Cell Stress Chaperones, 2008 Apr 8.
22. Li, Y.; Li, Y.; Liu, G.T. Protective effect of bicyclol on experimental liver fibrosis induced by carbon tetrachloride. Natl. Med. J. China, 2004, 84(24), 2096-2101.
23. Hu, Q.W.; Liu, G.T. Effects of bicyclol on dimethylnitosamine-induced liver fibrosis in mice and its mechanism of action. Life Sci., 2006, 79(6), 606-612.
24. Ju, M.H.; Li, Y. Metabolism of bicyclol in rat and human liver microsomes in vitro. Acta Pharm. Sin., 2005, 40(2), 111-116.
25. Liu, G.T.; Li, Y.; Wei, H.L.; Lu, H.; Zhang, H.; Gao, Y.G.; Wang, L.Z. Toxicity of novel anti-hepatitis drug Bicyclol: A preclinical study. World J. Gastroenterol., 2005, 11(5), 665-671.
26. Ji, Y.Y.; Cheng, N.N.; Yao, G.B. Pharmacokinetic study of bicyclol in thirty health volunteers. Chin. J. Clin. Pharmacol. Ther., 2001, 6(3), 218-221.
27. Yao, G.B.; Ji, Y.Y.; Wang, Q.H.; Zhou, X.Q.; Xu, D.Z.; Chen, X.Y.; Zhang, Q.B. A randomized double-blind controlled trial of bicyclol in treatment of chronic hepatitis B. Chin. J. New. Drugs Clin. Rem., 2002, 21, 457-461.
28. Yao, GB.; Ji, Y.Y.; Wang, Q.H.; Wu, W.F. Treatment of chronic hepatitis C by bicyclol, a randomized double-blind placebo controlled trial. Natl. Med. J. China, 2002, 82, 958-960.
29. Yao, G.B.; Xu, D.Z.; Lan, P.; Xu, C.B. Wang, C.; Luo, J.; Sheng, Y.M.; Li, Q. Efficacy and safety of bicyclol in treatment of 2200 chronic viral hepatitis. Chin. J. New Drugs Clin. Rem., 2005, 24(6), 421-425.
30. Jiang, J.J.; Kan, Z.C.; Jia, J. Analysis of chronic hepatitis B treated by bicyclol at different doses. Infect. Dis. Inform., 2005, 18, 80-81.
31. Guo, Q.; Zhang, Y.J.; Wang, J.; Su, C.L.; Chang, X. Evaluation of clinical usage of bicyclol in the treatment of chronic HCV. Evaluat. Anal. Drug Use Hospitals China, 2003, 3(6), 337-339.
32. Sun, J.M. Efficacy of bicyclol combined with rivabilin in the treatment of chronic hepatitis C patients failure or contradiction to interferon therapy. China Clin. Pract. Med., 2007, 1(8), 45-46.
33. Ye, X.G.; Wang, R.L. Comparison of anti-HBV and liver function recovery between bicyclol and lamivudine in treating chronic hepatitis B. Chin. J. Clin. Pharm., 2005, 14(2), 74-76.
34. Tao, X.H. Therapy of bicyclol combined with lamivudine in 28 patients resistance to lamivudine. ZheJiang Tradit. Chin. West. Med., 2005, 15, 428-429.
35. Huang, Y.C.; Xu, D.; Zhang, Z.G.; Tian, D.Y.; Qi, J.Y. Clinical study of sequential treatment of bicyclol in patients after treatment of lamivudine. Chin. J. Pharmacoepidemiol., 2005, 14(6), 321-323.
36. Zhu, C.L.; Chen, J.M.; Huangpu, Y.S.; Zhang, L.X. Clinical observation of the efficacy of sequential therapy of bicyclol and lamivudine in rebound after stopped lamivudine in chronic hepatitis B. Infect. Dis. Inform., 2006, 19(2), 79.
37. Wan, X.F.; Yang, Z.J.; Zhang, L.M.; Zhu, Y.F.; Zhuge, C.D. Lamivudine alone or in combination with bicyclol to treat chronic viral hepatitis B: A clinical study. Chin. J. Nosocomiol., 2006, 16(7), 811-813.
38. Shen, W.; Wang, X.Y.; Dong, X.; Xie, C.J.; Chen, B.L. Dynamic observation of combination therapy on serum HBV markers of chronic hepatitis B patients. Clin. Focus, 2004, 19(23), 1359-1360.
39. Zeng, J.H.; Yang, T.X. Effect of lamivudine combined bicyclol therapy on mutant hepatitis B virus. Pract. Med. J., 2007, 239(17), 2741.
40. Wu, X.L.; Wang, H.X.; Zhong, G.Q. Study of clinical curative effect of bicyclol combined with lamivudine in treatment of chronic hepatitis B and the influence on T cell subset. Eval. Anal. Drug Use Hospitals China, 2005, 5(4), 235-237.
41. Yu, J.G.; Shang, Q.H.; An, Y. Effectiveness and safety of adefovir dipivoxil combined with bicyclol in treatment of chronic hepatitis B. Infect. Dis. Inform., 2007, 20(5), 299-301.
42. Yu, B.L.; Liu, T.Y.; Wei, S.Y. Efficacy of bicyclol combined with FCV in the treatment of chronic hepatitis B. Infect. Dis. Inform., 2004, 17(2), 57.
43. α-2b alone and combined with bicyclol in the treatment of chronic viral hepatitis B. ZheJiang Clin. Med., 2006, 8(9), 904-905.
44. Liang, X.G.; Liu, W.D.; Wang, J.F.; Chen, B.X. Clinical observation of combination therapy of bicyclol with interferon-α in the therapy of positive HBeAg patients. Infect. Dis. Inform., 2007, 20(2), 115-116.
45. ShI, B.B.; Peng, J.; Wen, F.Y.; Hou, J.L. Effect of bicyclol tablets on cellular immune responses in patients with chronic hepatitis B. J. First Mil. Med. Univ., 2005, 25(6), 705-706.
46. Xia, Q.Y.; Zheng, J.L.; Zhou, Y.J.; Wang, C.X. Effect of bicyclol on cellular immune function of chronic viral hepatitis B patient. Infect. Dis. Inform, 2005, 18(3), 137-138.
47. Yi, J.H.; Li, W.; Xiong, Y. Clinical study on bicyclol against liver fibrosis induced by chronic hepatitis B. J. Clin. Intern. Med., 2006, 23(1), 57-59.
48. Yi, J.H.; Li, W.; Zeng, L.L.; Luo, D.D. Effect and mechanism of bicyclol on the hepatic fibrotic patients with chronic hepatitis B. J. Dalian Univ., 2006, 27(4), 27-30.
49. Wang, X.H. Clinical observation of bicyclolin the treatment of early liver fibrosis of chronic hepatitis B. Proc. Clin. Med. J., 2005, 14, 143-44.
50. Sun, J.M.; Zhu, Z.; Hu, Q.J. Clinical observation on bicyclol combined with ribavirin in the treatment of hepatitis C hepatocirrhosis. Chin. J. Dial. Artif. Organs, 2007, 18(3),16-17.
51. Zhu, B.; Liu, G.T.; Wu, R.S.; Strada, S.J. Chemoprevention of bicyclol against hepatic preneoplastic lesions. Cancer Biol. Ther., 2006, 5(12), 1665-1673.
52. Sun, H.; Liu, G.T. Chemopreventive effect of bicyclol on malignant transformation of WB-F344 rat liver epithelial cells and its effect on related signal transduction in vitro. Cancer Lett., 2006, 236, 239-249.
53. Zhu, B.; Liu, G.T.; Zhao, Y.M.; Wu, R.S.; Strada, S.J. Chemosensitizing multiple drug resistance of human carcinoma by bicyclol involves attenuated p-glycoprotein, GST-P and Bcl-2. Cancer Biol. Ther., 2006, 5, 536-543.